BlueCrow Capital

Maven is a SaaS pet tech startup that provides a personal vet to track the pet’s safety and health 24/7. It focuses on using technology to improve the quality of life for pets, as well as offering pet owners peace of mind and a way to keep track of their pet's safety, health, and well-being on a continual basis through their own personal veterinarian. It was started by the founders of Findster Technologies in 2021 and is based in the US and Portugal.

Tonic App S.A. is a technology company based in Porto, Portugal, that has developed a mobile application designed to enhance communication and collaboration among medical professionals. The application supports doctors by enabling messaging, sharing, and archiving of patient cases, as well as facilitating expert consultations and networking opportunities. It serves various stakeholders in the healthcare sector, including hospitals, pharmaceutical companies, and medical associations, to connect medical doctors with their peers and relevant communities. Additionally, the application provides access to essential medical content, allows for the coordination of urgent procedures, and enables discussions on clinical cases. With features like video consultations, prescription tools, and clinical decision support resources, Tonic App aims to improve the efficiency of clinical practices and ultimately enhance patient outcomes. Established in 2016, the company is recognized for its commitment to quality and safety in its clinical algorithms.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.